COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, has produced morbidity and death in staggering numbers. At the time of this writing, COVID-19 is responsible for more than 210,000 deaths worldwide, including more than 56,000 deaths in the United States alone Continue reading →

Myocardial Infarction Drug Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail Continue reading →

The combination of pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel-maintained improvements in survival for more than 8 years of follow-up in the first-line treatment of patients with HER2-positive metastatic breast cancer, according to long-term results from the phase III CLEOPATRA study published in theLancet Oncology. This represents the longest known follow-up for this patient population. Continue reading →

The incidence of thrombotic complications in patients with coronavirus disease 2019 (COVID-19) admitted to intensive care units (ICUs) appears to be remarkably high, according to the authors of a recent study published in Thrombosis Research. Frederikus A. Klok, MD, PhD, of the department of thrombosis and hemostasis at the Leiden University Medical Center in the Netherlands, and colleagues evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep vein thrombosis, ischemic stroke, myocardial infarction, or systemic arterial embolism in all COVID-19 patients admitted to the ICU of 2 university hospitals and 1 teaching hospital in the Netherlands Continue reading →

INDIANAPOLIS, May 8, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA)approved Retevmo (selpercatinib, 40 mg & 80 mg capsules), the first therapy specifically indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC),and the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Continue reading →

Patients with chronic lower extremity artery disease (LEAD) treated with a more vs less intensive antithrombotic therapeutic regimen were found to be at lower risk for limb amputation, stroke, and revascularization, according to a study published in the European Heart Journal-Cardiovascular Pharmacotherapy. An estimated 202 million people worldwide are thought to have LEAD Continue reading →